An important trial by Schwartzberg et al. has recently been published in The Oncologist. In prospective manner, this trial tested the two erythropoietin preparations commonly used in the US, epoetin […]
The debate of blood transfusion and cancer recurrence continues in this study. The authors found LN status and >3 units of blood transfused to be poor prognostic factors, but this […]
A nicely done placebo controlled trial of darbepoetin in anemic hematologic malignancy patients demonstrating darbepoetin’s efficacy and safety. – David H. Henry
This is an important EPO trial in hematologic malignancy patients for two reasons. It demonstrates that lower EPO levels predict response… an observation not reproduced in solid tumor patients but […]
This is a well done study of anemic cancer patients on cisplatin chemotherapy that documents nicely that the best predictor of an ultimate good response to epoetin is an early […]
Excellent design. – Patricia Ford
This is a case report of two female patients with severe vaginal bleeding following previous treatment of gynecological malignancies and no pre-existing coagulation factor deficiency. Bleeding was controlled with two […]
This prospective study did not demonstrate a beneficial effect of acute normovolemic hemodilution (ANH) in patients undergoing cervicofacial and ENT surgery. However, it does not possess the statistical power to […]
NATA: Network for the advancement of Patient Blood Management, Haemostasis and Thrombosis
MISSION: Providing a multidisciplinary forum for dialogue between haematologists, transfusion medicine specialists, anaesthesiologists, intensive care and emergency physicians, surgeons, perfusionists, nurses, biomedical scientists and ther healthcare professionals.
I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.